Biodesix Raises $8.8M More

Boulder-based Biodesix, a developer of diagnostic tests for the personalized medicine market, has raised $8.8M in a follow-on sale of its Series D preferred shares, the firm announced. The firm said the funding came from its existing investors. Names of those investors were not announced. Biodesix said it will use the funds for ongoing development of its technology platform, plus sales and marketing. Biodesix is developing diagnostic tests for a number of conditions; the firm said its first product is a serum protein test for guiding the treatment of patients with advanced non-small cell lung cancer (NSCLC). More information »